Page 1

Q32 BIO Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36 - week topline results from Part B of SIGNAL - AA clinical trial ; additional details from 36 - week results and initial findings from 52 - week results to be presented at a medical conference in the second half of 2026 -- - Patient enrollment and dosing in SIGNAL - AA Part B open - label extension ( OLE ) ongoing -- -- Registration - directed program evaluating bempikibart in patients with severe or very severe AA expected to initiate in 1H'2027 subject to planned regulatory discussions later this year -- -- Half - life extended fully human anti - IL - 7Ra antibody , ADX - 914 - XL , advancing in pre - clinical development -- -- Completed $ 200 million public offering in July 2026 -- - Cash and cash equivalents of $ 106.3 million as of June 30 , 2026 , combined with proceeds from July 2026 public offering , are expected to provide financial runway through Phase 3 topline results from planned registration- directed program WALTHAM , Mass.- August 5 , 2026 - Q32 Bio Inc. ( Nasdaq : QTTB ) ( “ Q32 Bio " ) , a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ( “ AA ” ) and other autoimmune and inflammatory diseases , today reported financial results for the quarter ended June 30 , 2026 , and provided recent corporate updates . " Our progress so far this year has been transformative for Q32 Bio and our bempikibart development program . In July , we reported positive topline results from Part B of our SIGNAL - AA program , demonstrating clinically meaningful efficacy , preliminary signs of durability , and a well - tolerated safety profile in patients with severe and very severe alopecia areata . We look forward to sharing additional details from our 36 - week results and initial findings from our 52 - week results at an upcoming medical meeting , " said Jodie Morrison , Chief Executive Officer of Q32 Bio . " The emerging profile of bempikibart represents a compelling opportunity to address the shortcomings of currently available treatments for patients in need of an effective , safe , and more durable alternative . We believe our data has set the bar for a biologic in alopecia areata and demonstrates the potential for bempikibart to become a standard of care , first - line option for patients . " Ms. Morrison added , " With our recently completed public offering and 36 - week Part B results , we are well positioned to advance planned regulatory discussions and initiate a registration - directed program evaluating bempikibart in severe and very severe alopecia areata in the first half of 2027. Additionally , we believe the results observed across bempikibart development to date represent a foundation for broader development , and we are currently evaluating opportunities in expanded alopecia areata populations , as well as in additional I & I indications where IL - 7 and TSLP signaling play a role . In parallel , we are advancing a half - life extended development candidate with the same mechanism of action as bempikibart . ”